Immunotherapy directly into fluid cavities shows promise for pancreatic cancer
NCT ID NCT07230301
First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests whether putting an immunotherapy drug (adebrelimab) directly into the chest or belly fluid can help control cancer-related fluid buildup in people with advanced pancreatic cancer. About 20 adults will receive the drug plus standard care. The goal is to see if this approach is safe and helps patients live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.